unknown
Stage
1
Investors
About
Brainvectis is a French biotech company developing innovative gene therapies for neurodegenerative diseases, with a primary focus on Huntington's disease. It originated as a spin-off from the French Alternative Energies and Atomic Energy Commission (CEA) and the University of Paris-Saclay.
Explore Brainvectis's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.